Scholarlink

<p>Simvastatin has demonstrated potential benefits in implant dentistry, primarily in animal studies. However, human evidence remains limited, making it essential to assess its effects on peri-implant bone health, soft tissue response, and implant stability. This systematic review, registered in PROSPERO (CRD420251001290) and conducted according to PRISMA guidelines, included human studies evaluating simvastatin use in partially edentulous patients receiving dental implants. A comprehensive search of PubMed, Embase, Scopus, Web of Science, Ovid MEDLINE and Google Scholar up to June 2025 was performed. Eligible studies assessed crestal bone changes, soft tissue outcomes, and implant stability. Data extraction and risk of bias assessment were carried out independently by two reviewers. Random-effects models, with subgroup and heterogeneity analyses, were used to compare outcomes between simvastatin and control groups. Six studies involving 175 participants were included. All reported significant improvements in crestal bone level (CBL) with simvastatin (<i>P</i> = 0.05 to 0.001). Two studies demonstrated significant increases in bone width (<i>P</i> &lt; 0.05) and bone density (<i>P</i> &lt; 0.001). Two studies found no significant differences in Implant Stability Quotient (ISQ) (<i>P</i> &gt; 0.05). Additionally, two studies reported significant reductions in bleeding on probing (BOP) (<i>P</i> &lt; 0.05) and probing depth (PD) (<i>P</i> &lt; 0.001). Overall, the risk of bias ranged from low to moderate. Simvastatin may enhance peri-implant bone health by reducing bone loss, increasing bone density, and supporting soft tissue healing. These findings highlight its potential as an adjunctive therapy, particularly in cases requiring improved bone regeneration and stability. Further clinical trials are needed to standardize dosing protocols, delivery methods, and assess long-term effectiveness.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

The efficacy of simvastatin in enhancing peri-implant bone health: a systematic review and meta-analysis of clinical trials

  • 期刊论文

  • 发表日期：

    2026年3月3日

查看全文
  • Sanjana Santhosh Kumar,
  • Saranya Pandurangan,
  • Raquel Cantillo,
  • Rachel Chacko,
  • Karthik Kommuri,
  • Abdul Basir Barmak,
  • Junad Khan,
  • Anuj Gupta

摘要

Simvastatin has demonstrated potential benefits in implant dentistry, primarily in animal studies. However, human evidence remains limited, making it essential to assess its effects on peri-implant bone health, soft tissue response, and implant stability. This systematic review, registered in PROSPERO (CRD420251001290) and conducted according to PRISMA guidelines, included human studies evaluating simvastatin use in partially edentulous patients receiving dental implants. A comprehensive search of PubMed, Embase, Scopus, Web of Science, Ovid MEDLINE and Google Scholar up to June 2025 was performed. Eligible studies assessed crestal bone changes, soft tissue outcomes, and implant stability. Data extraction and risk of bias assessment were carried out independently by two reviewers. Random-effects models, with subgroup and heterogeneity analyses, were used to compare outcomes between simvastatin and control groups. Six studies involving 175 participants were included. All reported significant improvements in crestal bone level (CBL) with simvastatin (P = 0.05 to 0.001). Two studies demonstrated significant increases in bone width (P < 0.05) and bone density (P < 0.001). Two studies found no significant differences in Implant Stability Quotient (ISQ) (P > 0.05). Additionally, two studies reported significant reductions in bleeding on probing (BOP) (P < 0.05) and probing depth (PD) (P < 0.001). Overall, the risk of bias ranged from low to moderate. Simvastatin may enhance peri-implant bone health by reducing bone loss, increasing bone density, and supporting soft tissue healing. These findings highlight its potential as an adjunctive therapy, particularly in cases requiring improved bone regeneration and stability. Further clinical trials are needed to standardize dosing protocols, delivery methods, and assess long-term effectiveness.